Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stubborn hip pain: TAME vs PRP showdown

NCT ID NCT07396246

Symptom relief Sponsor: Unidade Local de Saúde do Alto Ave, EPE Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two minimally invasive treatments for people with long-lasting hip pain (Greater Trochanteric Pain Syndrome). Participants will receive either a targeted artery treatment (TAME) or a platelet-rich plasma (PRP) injection. The goal is to see which one reduces pain and improves daily function better over a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of GTPS confirmed by clinical and imaging assessments * Persistent symptoms despite at least 3 months of conservative treatment (e.g., physical therapy, NSAIDs) * Willingness to participate and provide informed consent * Availability for follow-up assessments at 1, 3, 6, and 12 months post-treatment Exclusion Criteria: * Prior hip surgery or other interventions (e.g., joint replacement, prior PRP injections or embolization) * Severe osteoarthritis (Tonnis III) * Active lumbar radiculopathy with pain, numbness, or weakness in a dermatomal distribution * Contraindications for PRP injections (e.g., active infection, coagulopathy, antiplatelet or anticoagulation therapy, * Pregnancy or breastfeeding * Severe comorbidities that would interfere with participation * Active cancer or other malignancies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Trochanteric syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Trochanteric syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unidade Local de Saúde do Alto Ave

    RECRUITING

    Guimarães, Portugal